Neurocrine Biosciences to Participate at Investor Conferences in September
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Neurocrine Bio. (NBIX) PT Lowered to $128 at BMO Capital
August 28, 2024 4:16 PM EDTBMO Capital analyst Evan David Seigerman lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $128.00 (from $142.00) while maintaining a Market Perform rating.
The analyst comments "Dose response, where art thou? Highly anticipated '568 readout in schizophrenia was a head scratcher at... More
